[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,494
  • Shares Outstanding, K 87,874
  • Annual Sales, $ 30,910 K
  • Annual Income, $ -209,470 K
  • EBIT $ -171 M
  • EBITDA $ -170 M
  • 60-Month Beta 0.34
  • Price/Sales 12.19
  • Price/Cash Flow N/A
  • Price/Book 4.61

Options Overview Details

View History
  • Implied Volatility 388.62% (+108.90%)
  • Historical Volatility 67.47%
  • IV Percentile 89%
  • IV Rank 45.69%
  • IV High 755.94% on 03/03/26
  • IV Low 79.60% on 05/18/26
  • Expected Move (DTE 18) 0.53 (12.17%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 31
  • Volume Avg (30-Day) 928
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 20,253
  • Open Int (30-Day) 14,047
  • Expected Range 3.80 to 4.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 2
  • High Estimate $-0.45
  • Low Estimate $-0.45
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.00 +8.25%
on 05/21/26
6.10 -29.02%
on 05/06/26
-1.07 (-19.81%)
since 04/29/26
3-Month
4.00 +8.25%
on 05/21/26
6.80 -36.28%
on 04/17/26
-1.39 (-24.30%)
since 02/27/26
52-Week
4.00 +8.25%
on 05/21/26
11.24 -61.49%
on 09/05/25
-3.28 (-43.10%)
since 05/28/25

Most Recent Stories

More News
Verastem Oncology to Present at Jefferies Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 4.33 (+0.93%)
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael...

VSTM : 4.33 (+0.93%)
Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 4.33 (+0.93%)
Verastem Q1 Earnings Call Highlights

Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade serous...

VSTM : 4.33 (+0.93%)
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Available at LGSOCAwarenessDay.Org, the LGSOC Resource Guide brings together resources from patient advocacy groups, covering topics from diagnosis to survivorship

VSTM : 4.33 (+0.93%)
Verastem: Q1 Earnings Snapshot

Verastem: Q1 Earnings Snapshot

VSTM : 4.33 (+0.93%)
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth ...

VSTM : 4.33 (+0.93%)
Verastem's RAS Pathway Pipeline Now Matters More Than Its Approved Product

Barchart Research What to Expect from VSTM Earnings VSTM Generated May 6, 2026 Current Price $6.01 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 6.04% Verastem's RAS Pathway Pipeline Now...

VSTM : 4.33 (+0.93%)
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Low-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer with a high rate of recurrence affecting more than 80% of patients Integrated healthcare professional...

VSTM : 4.33 (+0.93%)
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference...

VSTM : 4.33 (+0.93%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 4.60
2nd Resistance Point 4.50
1st Resistance Point 4.42
Last Price 4.33
1st Support Level 4.23
2nd Support Level 4.13
3rd Support Level 4.05

See More

52-Week High 11.24
Fibonacci 61.8% 8.48
Fibonacci 50% 7.62
Fibonacci 38.2% 6.77
Last Price 4.33
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.